Biomarin

BioMarin Cruises While It Waits on Seventh Approval
BioMarin Cruises While It Waits on Seventh Approval
Motley Fool
Biomarin
pegvaliase
FDA
PKU
earnings
Flag link:
8 Takeout targets to watch in 2018
8 Takeout targets to watch in 2018
BioPharma Dive
M&A
Allergan
Alnylam
Biomarin
Bristol-Myers Squibb
Incyte
Madrigal Pharmaceuticals
Spark Therapeutics
Sucampo
Flag link:
[video]ASH 2017 Recap: These Were the Big Winners and Losers
[video]ASH 2017 Recap: These Were the Big Winners and Losers
Motley Fool
ASH2017
Bluebird Bio
Juno Therapeutics
Spark Therapeutics
Biomarin
JNJ
Celgene
Flag link:
ASH 2017: What you missed
ASH 2017: What you missed
BioPharma Dive
ASH17
Biomarin
Spark Therapeutics
Gilead Sciences
Novartis
Juno Therapeutics
AbbVie
Roche
JNJ
Flag link:
5 Biotech Buyout Candidates for 2018
5 Biotech Buyout Candidates for 2018
Yahoo/Motley Fool
biotech
M&A
Biogen
Biomarin
Bluebird Bio
Geron
SAGE Therapeutics
Flag link:
ASH17: Spark gene therapy falls behind BioMarin in hemophilia
ASH17: Spark gene therapy falls behind BioMarin in hemophilia
BioPharma Dive
ASH17
Spark Therapeutics
gene therapy
Biomarin
hemophilia A
SPK-8011
Flag link:
ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia
ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia
BioPharma Dive
ASH17
Biomarin
gene therapy
hemophilia A
valoctocogene
Flag link:
How much is an FDA shortcut worth to drug developers hustling to an OK? Holding steady at $125M, cash
How much is an FDA shortcut worth to drug developers hustling to an OK? Holding steady at $125M, cash
Endpoints
FDA
priority review vouchers
Biomarin
Flag link:
9 Notable Biotechs Presenting At This Year's ASH Meeting
9 Notable Biotechs Presenting At This Year's ASH Meeting
Yahoo
ASH
Bluebird Bio
LentiGlobin
Ziopharm Oncology
Bellicum
BPX-501
Spark Therapeutics
SPK-8011
Biomarin
BMN 270
Juno Therapeutics
CAR-T
Novartis
Geron
imetelstat
Immunogen
IMGN632
IMGN779
Flag link:
With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy
With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy
Endpoints
Biomarin
gene therapy
BMN 270
hemophilia A
Flag link:
BioMarin says the FDA game clock now ticking on their blockbuster hopeful pegvaliase
BioMarin says the FDA game clock now ticking on their blockbuster hopeful pegvaliase
Endpoints
Biomarin
FDA
pegvaliase
PDUFA
Flag link:
Biomarin announces new investments in Ireland
Biomarin announces new investments in Ireland
GoInPharma
Biomarin
Ireland
Flag link:
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
Endpoints
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Flag link:
BioMarin, Spark, raising the stakes for hemophilia
BioMarin, Spark, raising the stakes for hemophilia
BioPharma Dive
Biomarin
Spark Therapeutics
hemophilia
BMN 270
SPK-9001
gene therapy
Flag link:
BioMarin CEO says 'the system will have to determine' the worth of its new $702,000 drug
BioMarin CEO says 'the system will have to determine' the worth of its new $702,000 drug
CNBC
Biomarin
Brineura
drug pricing
Batten disease
Flag link:
4 Drug Stocks With Big News Coming in April
4 Drug Stocks With Big News Coming in April
Motley Fool
Neurocrine
Incyte
Eli Lilly
Biomarin
Ingrezza
baricitinib
Brineura
Flag link:
BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster
BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster
Motley Fool
Biomarin
earnings
Vimizim
Kuvan
Naglazyme
Flag link:
BioMarin sues to stop generic version of its $90K-a-year drug
BioMarin sues to stop generic version of its $90K-a-year drug
Bizjournals.com
Biomarin
generics
Kuvan
Dr Reddy's
Flag link:
Biotech Investing: 3 Bold Predictions for 2017
Biotech Investing: 3 Bold Predictions for 2017
Motley Fool
biotech
Incyte
Biogen
Biomarin
Gilead Sciences
Illumina
Flag link:
7 of the Most Shocking Biotech Pipeline Blowups of 2016
7 of the Most Shocking Biotech Pipeline Blowups of 2016
Motley Fool
biotech
Alnylam
revusiran
Clovis Oncology
rociletinib
Celldex Therapeutics
Rintega
Eli Lilly
solanezumab
Novavax
RSV-F
Arrowhead
ARC-520
ARC-521
ARC-AAT
Biomarin
drisapersen
Flag link:

Pages